Effectiveness of ophthalmic solution preservatives: A comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system

BMC Ophthalmology

Volumn 11, Issue 1, 2011, Pages

  Ryan, Gerard ^a   Fain, Joel M ^a   Lovelace, Cherie ^b   Gelotte, Karl M ^a  

^a PFIZER INC   (United States)

^b Independent Research Consultant   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; BENZALKONIUM; CLOPROSTENOL; DRUG DERIVATIVE; EYE DROPS; LATANOPROST; PRESERVATIVE; PROSTAGLANDIN F; TRAVOPROST;

ARTICLE; BACTERIUM; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; FUNGUS; HUMAN; STEM CELL;

ANTI-INFECTIVE AGENTS; ANTIHYPERTENSIVE AGENTS; BACTERIA; BENZALKONIUM COMPOUNDS; CLOPROSTENOL; DRUG EVALUATION, PRECLINICAL; FUNGI; HUMANS; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F, SYNTHETIC; STEM CELLS;

EID: 79954611170     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-11-8     Document Type: Article

References (30)

1. Microbial contamination of in-use ocular medications. OD Schein PL Hibberd T Starck AS Baker KR Kenyon, Arch Ophthalmol 1992 110 82 85 1731727
2. Microbial contamination of medications used to treat glaucoma. O Geyer EJ Bottone SM Podos RA Schumer PA Asbell, Br J Ophthalmol 1995 79 376 379 10.1136/bjo.79.4.376 7742288
3. An objective evaluation of eyedrop instillation in patients with glaucoma. JL Stone AL Robin GD Novack DW Covert GD Cagle, Arch Ophthalmol 2009 127 732 736 10.1001/archophthalmol.2009.96 19506189
4. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. AL Hennessy J Katz D Covert C Protzko AL Robin, Ophthalmology 2010 117 2345 2352 10.1016/j.ophtha. 2010.03.040 20580092
5. Self-sterilizing ophthalmic solutions. SD McPherson Jr RM Wood, Am J Ophthalmol 1949 32 675 678 18121097
6. Ocular preservatives: associated risks and newer options. IP Kaur S Lal C Rana S Kakkar H Singh, Cutan Ocul Toxicol 2009 28 93 103 10.1080/ 15569520902995834 19505226
7. US product insert. Travatan Z (travoprost ophthalmic solution), Alcon Laboratories, Fort Worth, TX 2006, 2010. http://ecatalog.alcon.com/pi/TravatanZ- us-en.pdf
8. US product insert. Xalatan (latanoprost ophthalmic solution), Pfizer Inc, New York, NY 2009 http://media.pfizer.com/files/products/uspi-xalatan.pdf
9. Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium. N Nagai T Murao N Okamoto Y Ito, J Oleo Sci 2010 59 135 141 20124755
10. European public assessment report (EPAR) Travatan. European Medicines Agency, 2007 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medici nes/000390/human-med-001102.jsp&murl=menus/medicines/medicines. jsp&mid=W C0b01ac058001d125
11. Efficacy of antimicrobial preservation. European Directorate for the Quality of Medicines, European Pharmacopoeia Strasbourg: European Directorate for the Quality of Medicines 6 2006 5129 5130
12. The United States Pharmacopeia Convention, United States Pharmacopeia/National Formulary Rockville: US Pharmacopeia 2009
13. Japanese Pharmacopoeia. Ykuji Nippo Ltd, Tokyo: Maruzen Co., Ltd 15 2006
14. SofZia preservative system meets United States Pharmacopeia standards. RJ Noecker, EyeWorld 2007 http://www.eyeworld.org/article.php?morphologic= &query=&sid=3734&strict=
15. Recurrent bleb infections. S Waheed JM Liebmann DS Greenfield DC Ritterband JA Seedor M Shah R Ritch, Br J Ophthalmol 1998 82 926 929 10.1136/bjo.82.8.926 9828779 (Pubitemid 28408153)
16. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. TM Aaberg Jr HW Flynn Jr J Schiffman J Newton, Ophthalmology 1998 105 1004 1010 10.1016/S0161-6420(98)96000-6 9627649 (Pubitemid 28268323)
17. Endophthalmitis caused by Pseudomonas aeruginosa. CW Eifrig IU Scott HW Flynn Jr D Miller, Ophthalmology 2003 110 1714 1717 10.1016/S0161-6420(03)00572- 4 13129867 (Pubitemid 37028308)
18. Are multidose over-the-counter artificial tears adequately preserved? C Charnock, Cornea 2006 25 432 437 10.1097/01.ico.0000183538.53017.69 16670481 (Pubitemid 44620128)
19. Ocular tolerance of preservatives and alternatives. P Furrer JM Mayer R Gurny, Eur J Pharm Biopharm 2002 53 263 280 10.1016/S0939-6411(01)00246-6 11976014 (Pubitemid 34303289)
20. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. JC Henry JH Peace JA Stewart WC Stewart, Clin Ophthalmol 2008 2 613 621 19668762
21. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. MB Horsley MY Kahook, Clin Ophthalmol 2009 3 291 295 19668581
22. A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension. DA Godfrey LS Peplinski JA Stewart WC Stewart, Clin Ophthalmol 2009 3 189 194 19668564
23. Dry eye and irritation comparison of latanoprost 0.005% with the preservative benzalkonium chloride (BAC) versus travoprost 0.004% without BAC. JR Townley C Reilly, Invest Ophthalmol Vis Sci 2009 50 E-Abstract 4651
24. Ocular surface changes in patient using latanoprost and travoprost with ssofZia. CJ Cruz-Colon J Myers J Katz T Tai S Wizov J Wittpenn MR Moster M Pro CJ Rapuano, Invest Ophthalmol Vis Sci 2010 51 E-Abstract 168.
25. Prevalence of ocular surface disease in glaucoma patients. EW Leung FA Medeiros RN Weinreb, J Glaucoma 2008 17 350 355 10.1097/IJG.0b013e31815c5f4f 18703943
26. Incidence of dry eye or ocular infection in open-angle glaucoma (OAG) and ocular hypertension (OH) patients treated with latanoprost (LAT) with BAK or travoprost-Z (TRAV-Z) with SofZia S Kotak GF Schwartz J Mardekian J Fain, Invest Ophthalmol Vis Sci 2010 51 E-Abstract 2762.
27. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. T Bourcier F Thomas V Borderie C Chaumeil L Laroche, Br J Ophthalmol 2003 87 834 838 10.1136/bjo.87.7.834 12812878 (Pubitemid 36765243)
28. Bacterial keratitis: a prospective clinical and microbiological study. F Schaefer O Bruttin L Zografos Y Guex-Crosier, Br J Ophthalmol 2001 85 842 847 10.1136/bjo.85.7.842 11423460 (Pubitemid 32662086)
29. Microbial keratitis predisposing factors and morbidity. L Keay K Edwards T Naduvilath HR Taylor GR Snibson K Forde F Stapleton, Ophthalmology 2006 113 109 116 10.1016/j.ophtha.2005.08.013 16360210 (Pubitemid 43021736)
30. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. RA Lewis GJ Katz MJ Weiss TA Landry JE Dickerson JE James SY Hua EK Sullivan DB Montgomery DT Wells MVW Bergamini, J Glaucoma 2007 16 98 103 10.1097/01.ijg.0000212274.50229.c6 17224758 (Pubitemid 46114782)